HHS Notice on Exclusive Patent License for Catheter Ablation Lawsuit

The Department of Health and Human Services published a notice on November 2, 2026, stating that the National Heart, Lung and Blood Institute is contemplating the grant of an exclusive patent license to AntaraCore, Systems, Inc. of Dover, Delaware. The notice covers inventions claimed in patent applications for catheter-based intramyocardial ablation to treat ventricular arrhythmia in a human. No license has been granted. The notice sets a December 2, 2026 deadline for written comments and competing license applications.

At a glance

• The document is Federal Register notice 2026-22339, published November 2, 2026, at 91 FR 68963.
• The agency involved is the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), within the Department of Health and Human Services.
• The contemplated licensee is AntaraCore, Systems, Inc., located in Dover, Delaware.
• The license under consideration is described by the agency as exclusive.
• Written comments and license applications must reach the NHLBI Office of Technology Transfer and Development by December 2, 2026.

What the November 2, 2026 notice actually says

The notice is captioned “Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human.” Its stated action is “Notice,” and it runs two pages, from 68963 to 68964 of volume 91 of the Federal Register.

The agency’s abstract says NHLBI is “contemplating the grant of an exclusive patent license” to AntaraCore, Systems, Inc. The license would cover practice of inventions “embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice.” Because a Federal Register notice of this kind is a statement of intent, the operative word in the record is “contemplating.”

The notice names the recipient’s location as Dover, Delaware. It does not, in the record reviewed for this article, describe AntaraCore’s ownership, financing, clinical history or manufacturing arrangements.

The dates field states that “only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development December 2, 2026 will be considered.” That sentence does two things at once: it opens a comment window and it invites competing applications for the same technology before the deadline.

What is established vs. what is alleged

Established by the Federal Register record:

• HHS, through NHLBI, published a notice with document number 2026-22339 on November 2, 2026.
• The notice announces a contemplated exclusive patent license, not a completed one.
• The named prospective licensee is AntaraCore, Systems, Inc. of Dover, Delaware.
• The subject matter is catheter-based intramyocardial ablation for treating ventricular arrhythmia in a human.
• A December 2, 2026 receipt deadline applies to comments and license applications.

Not established by the record: there is no allegation, claim or dispute in this document to weigh against the notice. A Federal Register notice of this type is an agency announcement, not a complaint, verdict or settlement. Nothing in the record reviewed characterizes the technology’s safety, efficacy or regulatory clearance status, and nothing asserts wrongdoing by AntaraCore or by any other party. Readers looking for a litigation posture will not find one here; the document is a technology transfer announcement.

How a federal patent license notice works

Federal laboratories such as NHLBI hold rights in inventions developed with federal funding. When an agency proposes to license such an invention, especially on an exclusive basis, it publishes notice in the Federal Register so that the public and interested companies can comment or apply.

The notice’s comment mechanism exists so that the agency can hear from parties who object to exclusivity or who say they can develop the invention. The same window lets other firms submit license applications that the agency would then weigh. The record here states only that materials received by December 2, 2026 will be considered; it does not describe the agency’s decision criteria.

Because this is a licensing announcement, it sits outside the litigation categories this publication usually covers, such as product recalls and consolidated injury claims. A reader comparing agency announcements with court records may find the pharmaceutical litigation case studies useful for contrast, since those pages track filed claims rather than licensing notices.

Where the claims stand procedurally

There is no court case, no MDL (multidistrict litigation, a procedure that consolidates related federal cases before one judge) and no docket number in this record. The only procedural markers are administrative: publication in the Federal Register on November 2, 2026 and the December 2, 2026 receipt deadline at the NHLBI Office of Technology Transfer and Development.

No trial date, appeal or adjudicated finding exists, because no adversarial proceeding is described. The next observable step in the public record would be an agency decision following the comment period. The notice itself does not promise that a license will issue, does not state when a decision would come, and does not address what happens if competing applications arrive.

Key dates

• November 2, 2026: HHS published Federal Register notice 2026-22339 at 91 FR 68963, announcing the contemplated exclusive patent license to AntaraCore, Systems, Inc.
• December 2, 2026: Deadline for written comments and license applications to be received by the NHLBI Office of Technology Transfer and Development.

What this does not establish

The notice does not grant a license. It announces that NHLBI is contemplating one.

The notice does not establish that the underlying catheter-based intramyocardial ablation technology is safe, effective or approved by any regulator. It says nothing about clinical trials, clearances or marketing status.

The notice does not establish AntaraCore’s corporate structure, finances or capacity to commercialize the invention. It identifies the company and its location only.

The notice does not resolve whether exclusivity will ultimately be granted. Nothing in the record addresses objections, competing applications, or the agency’s final determination.

The notice does not create any right or entitlement for patients, clinicians or other companies. It is an administrative announcement with a comment window.

Frequently asked questions

Did the government grant an exclusive patent license to AntaraCore, Systems, Inc.?

No. The Department of Health and Human Services notice 2026-22339, published November 2, 2026, states that the National Heart, Lung and Blood Institute is contemplating the grant of an exclusive patent license to AntaraCore, Systems, Inc. of Dover, Delaware. The document is an announcement of intent, not a completed grant. Any final decision would follow the comment period that closes December 2, 2026.

What technology does the notice cover?

The notice covers inventions for catheter-based intramyocardial ablation for treating ventricular arrhythmia in a human, as embodied in patent applications listed in the notice’s supplementary information section. The Federal Register abstract describes the license as one to practice those inventions. The document reviewed does not describe the devices, procedures or clinical data in detail.

Can another company still apply for this license?

Yes, the notice invites that. It states that only written comments and applications for a license received by the NHLBI Office of Technology Transfer and Development by December 2, 2026 will be considered. The same deadline applies to both comments and competing applications. The notice does not describe how the agency will weigh multiple applications.

Is this a lawsuit or a recall?

No. Federal Register notice 2026-22339 is an administrative licensing announcement from the Department of Health and Human Services, published November 2, 2026. It contains no complaint, no court, no verdict and no recall. Readers seeking product recall records can review the metoclopramide recall coverage for an example of how agency recall notices are documented.

Where was the notice published?

The notice appeared in the Federal Register on November 2, 2026, at volume 91, page 68963, with document number 2026-22339. Its agencies of record are the Department of Health and Human Services and the National Institutes of Health. The document runs two pages, ending at page 68964.

Sources

1. Federal Register (Office of the Federal Register): “Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human” (link, accessed 2026-11-02)
2. Federal Register (Office of the Federal Register): “All Documents” newest-first index, including document 2026-22339 (link, accessed 2026-11-02)
3. Federal Register (Office of the Federal Register): “Agencies” listing, including the Department of Health and Human Services and National Institutes of Health entries (link, accessed 2026-11-02)
4. Federal Register (Office of the Federal Register): “Documents of type Rule” index (link, accessed 2026-11-02)
5. Federal Register (Office of the Federal Register): “Documents of type Notice” index (link, accessed 2026-11-02)
6. Federal Register (Office of the Federal Register): “Documents of type Proposed Rule” index (link, accessed 2026-11-02)